



Biocon Ltd (OTC) Symbol : **BCLTF**  
 Sector: Healthcare  
 Industry: Pharmaceuticals

**Headquarters**

20th KM Hosur Road,  
 Electronics City,  
 Bangalore,  
 Karnataka 560100  
 TelePhone 91 80 2852 3434  
 Tollfree NA  
 www.biocon.com

**Business Summary**

Biocon Limited, an integrated biotechnology company, together with its subsidiaries, engages in the research, manufacture, and marketing of biopharmaceuticals products and enzymes worldwide. Its technologies develop biomolecules in diabetology, oncology, cardiology, and other therapeutic segments. The company's biopharmaceutical products comprise anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-oxidants, cardiovascular agents, digestive aid enzymes, haemostatic agents, hepatoprotective agents, immunosuppressants, and nutraceuticals. Its enzymes include amylases, cellulases, esterases, glucanases, hemicellulases/xylanases, oxidases, pectinases, proteases, and tannase. The company also provides custom research services in the areas of synthetic chemistry and molecular biology. Biocon's product BIOMAb EGFR, a monoclonal antibody, has completed Phase IIb clinical trials, for the treatment of head and neck cancers. It serves various industries, including animal healthcare, food, and beverage; brewing and gelatin; leather; textile; sugar; detergent; and paper and pulp. Biocon has partnerships with Vaccinex, Inc., CIMAB S.A., Nobex Corporation, and Centre of Molecular Immunology, as well as collaboration agreement with Innate Pharmaceuticals AB to develop virulence blockers for the treatment of bacterial diarrhoeal disease. The company, formerly known as Biocon India Limited, was founded in 1978 and changed its name to Biocon Limited in 2003. Biocon is headquartered in Bangalore, India.

**No. of Deals by Deal Category**

Listed are specific company Technology, Product and Miscellaneous Deals and Alliances which we have analyzed and have extracted from nearly 15,000 citations incorporated into the Deals and Alliances Database associated with MedTRACK. Our database extends back nearly 20 years and currently consists of over 7,500+ deals, mergers, alliances and is constantly be added to and updated. We have attempted to include the salient details as an overview for the company of interest. Additional specific deal information is available on a subscription basis at www.metrack.com. Specifics of a deal or deal search can be obtained by entering the MedTRACK Reference ID once logged onto MedTRACK.

- Technology Deals (1)
- Product Deals (10)
- Miscellaneous Deals (7)

Total Deals: 18

**List of Partners (20):**


Albany Molecular Research Inc	Bayer Ag	Bayer HealthCare	Bentley Pharmaceuticals	Cimab S.A
-------------------------------	----------	------------------	-------------------------	-----------

			Inc	
Dow Chemical Company	Elan Corp Plc	Ferozsons Laboratories Limited	GlaxoSmithKline plc	Innate Pharmaceuticals AB
National Institutes of Health (NIH)	Neopharma	Nobex Corporation	Novartis AG	OmniComm Systems, Inc.
Pfizer Inc	Pharmacia Corporation	Strand Life Sciences	The U.S. Department of Health and Human Services	Vaccinex, Inc.


**Deal Types:**

- Collaboration (8)
- Marketing (5)
- Co-development (4)
- Development (4)
- License (4)
- Research (3)
- Manufacturing (2)
- Joint Venture (2)
- Letter of Intent (1)
- Commercialization (1)
- Termination (1)


**Top Ten Deal Types for BCLTF**



**BCLTF Deals by Therapeutic Category**



### BCLTF Deals by Stage of Development



### Top Deals by Deal Value

Date	Source/Partner	Deal Type(s)	Deal Value (in \$mm)	Reference ID
5/22/2002	Nobex Corporation GlaxoSmithKline plc	Commercialization, Development, License, Termination	283.0	prod_12612002522
10/19/2000	National Institutes of Health (NIH) The U.S. Department of Health and Human Services Nobex Corporation	Development	0.2	comp_1058120001019

### Partners based on Technology

Date	Technology	Source/Partner	Deal Type(s)	Deal Value (in \$mm)
3/25/2002	Amphiphilic Polymer Conjugation Technology(Nobex Technology)	Nobex Corporation Pfizer Inc Pharmacia Corporation	Collaboration, Research	not disclosed

NOBEX Corporation formed a collaboration with Pharmacia Corporation. Proprietary medicinal chemistry developed by NOBEX will be used to modify an undisclosed Pharmacia protein to improve its oral delivery in pill or liquid form. Under the terms of the agreement, Pharmacia will fund research at NOBEX and has an option to license the NOBEX-modified drug at the completion of the study. ( MedTRACK Reference ID: tech\_50372002325)

### Partners based on Product

Date	Product Name	Source/Partner	Deal Type(s)	Indication	Deal Value (in \$mm)
1/18/2007	BIOMAb EGFR	Ferozsons Laboratories Limited	License, Marketing	Brain Tumor	not disclosed

Biocon announced that it has granted an exclusive license to Ferozsons Laboratories for marketing BIOMAb EGFR in Pakistan. The successful debut made by BIOMAb EGFR in the Indian market since mid-September, 2006, has evinced strong licensing interest for the proprietary cancer drug in the region. Biocon's decision to select Ferozsons Laboratories as its exclusive licensee in Pakistan was based on the leadership position that the company enjoys in Oncology. BIOMAb EGFR is indicated for Head and Neck

cancer and is being studied in global clinical trials for Colorectal, Lung Cancer, Glioma and Pancreatic cancers. ( MedTRACK Reference ID: prod\_281642007118)

1/18/2007	BIOMAb EGFR	Ferozsons Laboratories Limited	License, Marketing	Head and Neck Cancer	not disclosed
-----------	-------------	--------------------------------	--------------------	----------------------	---------------

Biocon announced that it has granted an exclusive license to Ferozsons Laboratories for marketing BIOMAb EGFR in Pakistan. The successful debut made by BIOMAb EGFR in the Indian market since mid-September, 2006, has evinced strong licensing interest for the proprietary cancer drug in the region. Biocon's decision to select Ferozsons Laboratories as its exclusive licensee in Pakistan was based on the leadership position that the company enjoys in Oncology. BIOMAb EGFR is indicated for Head and Neck cancer and is being studied in global clinical trials for Colorectal, Lung Cancer, Glioma and Pancreatic cancers. ( MedTRACK Reference ID: prod\_281642007118)

1/18/2007	BIOMAb EGFR	Ferozsons Laboratories Limited	License, Marketing	Non-Small-Cell Lung Cancer	not disclosed
-----------	-------------	--------------------------------	--------------------	----------------------------	---------------

Biocon announced that it has granted an exclusive license to Ferozsons Laboratories for marketing BIOMAb EGFR in Pakistan. The successful debut made by BIOMAb EGFR in the Indian market since mid-September, 2006, has evinced strong licensing interest for the proprietary cancer drug in the region. Biocon's decision to select Ferozsons Laboratories as its exclusive licensee in Pakistan was based on the leadership position that the company enjoys in Oncology. BIOMAb EGFR is indicated for Head and Neck cancer and is being studied in global clinical trials for Colorectal, Lung Cancer, Glioma and Pancreatic cancers. ( MedTRACK Reference ID: prod\_281642007118)

7/19/2006	Insugen	Bayer Ag Bayer HealthCare	License, Marketing	Diabetes	not disclosed
-----------	---------	---------------------------	--------------------	----------	---------------

Biocon Ltd has announced a licensing agreement with Bayer HealthCare for the exclusive marketing and trademark rights for INSUGEN for the Chinese market. It is envisaged that the collaboration will be expanded to other countries in Asia Pacific. After completion of necessary local registration trials, INSUGEN, a recombinant human insulin, is expected to be launched within the next two to three years in China. ( MedTRACK Reference ID: prod\_255242006719)

11/14/2005	Nasulin / Intranasal Insulin	Bentley Pharmaceuticals Inc	Development, License, Marketing	Diabetes	not disclosed
------------	------------------------------	-----------------------------	---------------------------------	----------	---------------

Bentley Pharmaceuticals, Inc., a technology-based specialty pharmaceutical and drug delivery company with a growing branded and generic product line in Europe, announced that it has signed a product licensing agreement with Biocon Limited for Bentley's intranasal spray formulation for administering insulin. The license agreement covers 85 countries granting Biocon exclusive as well as co-exclusive rights to develop and market Bentley's formulation throughout Asia, Africa, and the Middle East.

Bentley also announced that it has entered into a long term supply agreement with Biocon, which will provide Bentley, and its licensees, with a competitive commercial supply of insulin for worldwide markets. ( MedTRACK Reference ID: prod\_1885320051114)

8/23/2005	Oral hBNP ( NBN-002)	Nobex Corporation	Co-development, Collaboration	Congestive Heart Failure	not disclosed
-----------	----------------------	-------------------	-------------------------------	--------------------------	---------------

Nobex Corporation and Biocon Limited have signed a new agreement for the global co-development of an oral brain-type natriuretic peptide product for the treatment of cardiovascular disease.

The collaboration combines the proprietary oral peptide delivery technology of Nobex with the proven peptide production capabilities of Biocon. The firms will work closely together on all aspects of the product development process to focus on the development of an oral BNP product for the chronic treatment of heart failure and other potential cardiovascular indications. ( MedTRACK Reference ID: prod\_164952005823)

11/18/2004	BVX-10	Vaccinex, Inc.	Co-development	Inflammation	not disclosed
------------	--------	----------------	----------------	--------------	---------------

Vaccinex and Biocon Limited announced a broad strategic partnership to discover and co-develop at least four therapeutic antibody products. The collaboration combines Vaccinex's unique capabilities to discover fully human monoclonal antibodies using its proprietary antibody discovery technology and Biocon's proven expertise in clinical research and biologics manufacturing.

The parties will jointly identify promising antibody candidates and move them rapidly into clinical development, focusing on antibodies directed to cancer, inflammation and autoimmune disease. ( MedTRACK Reference ID: prod\_1029020041118)

11/18/2004	BVX-20	Vaccinex, Inc.	Co-development	Cancer	not disclosed
------------	--------	----------------	----------------	--------	---------------

Vaccinex and Biocon Limited announced a broad strategic partnership to discover and co-develop at least four therapeutic antibody products. The collaboration combines Vaccinex's unique capabilities to discover fully human monoclonal antibodies using its proprietary antibody discovery technology and Biocon's proven expertise in clinical research and biologics manufacturing.

The parties will jointly identify promising antibody candidates and move them rapidly into clinical development, focusing on antibodies directed to cancer, inflammation and autoimmune disease. ( MedTRACK Reference ID: prod\_1029020041118)

10/20/2004	Oral Insulin	Nobex Corporation	Co-development	Diabetes	not disclosed
------------	--------------	-------------------	----------------	----------	---------------

Nobex Corporation, a drug development company specializing in medicinal chemistry-based drug delivery and Biocon, Limited have entered into a joint development agreement for the global co-development of an oral insulin product for the treatment of diabetes. The collaboration combines the proprietary peptide oral-delivery and manufacturing technology of U.S.-based Nobex with the proven peptide production capabilities of Biocon, India's leading biotechnology company. The firms will focus on the development of an oral insulin product that can be used to treat a diabetic population that will increase to more than 200 million worldwide by the year 2030.

Both companies indicated that the collaborative effort in developing the oral insulin product will require several years to reach the market but that they expect to have meaningful clinical data and progress toward manufacturing within two years. ( MedTRACK Reference ID: prod\_931920041020)

2/17/2004	NLC-001	Nobex Corporation Dow Chemical Company	Collaboration	Obesity	not disclosed
-----------	---------	---	---------------	---------	---------------

The Dow Chemical Company and Nobex Corporation, a drug development company specializing in drug delivery, initiated collaboration on plant-based production of NLC-001, a proprietary peptide currently in preclinical development by Nobex as a potential appetite suppressant to treat obesity. Under the agreement, the initial expression of the peptide will take place in plant cell suspension to allow for fast evaluation of the ability of plant tissues to secrete the peptide. ( MedTRACK Reference ID: prod\_58672004217)

2/26/2003	EGF Cancer Vaccine	Cimab S.A	Joint Venture	Cancer	not disclosed
-----------	--------------------	-----------	---------------	--------	---------------

The Center of Molecular Immunology and its commercial branch CIMAB SA announced that both companies BIOCON India Ltd and CIMAB SA have finalized a joint venture agreement to establish a new Joint Venture company BIOCON Pharmaceuticals Ltd that will set up a new manufacturing facility to manufacture and market a select range of biotechnology products for human health care primarily in the Indian market.

In the JV agreement BIOCON India Ltd has tied-up with CIMAB SA in a 51:49 venture which also includes or will develop a monoclonal antibody for cancer treatment and other products from mammalian cell culture. ( MedTRACK Reference ID: prod\_84442003226)

2/26/2003	h-T1 humanized anti-CD6 Mab	Cimab S.A	Joint Venture	Cutaneous T-cell Lymphoma	not disclosed
-----------	-----------------------------	-----------	---------------	---------------------------	---------------

The Center of Molecular Immunology and its commercial branch CIMAB SA announced that both companies BIOCON India Ltd and CIMAB SA have finalized a joint venture agreement to establish a new Joint Venture company BIOCON Pharmaceuticals Ltd that will set up a new manufacturing facility to manufacture and market a select range of biotechnology products for human health care primarily in the Indian market.

In the JV agreement BIOCON India Ltd has tied-up with CIMAB SA in a 51:49 venture which also includes or will develop a monoclonal antibody for cancer treatment and other products from mammalian cell culture. ( MedTRACK Reference ID: prod\_84442003226)

2/26/2003	h-T1 humanized anti-CD6 Mab	Cimab S.A	Joint Venture	Rheumatoid Arthritis	not disclosed
-----------	-----------------------------	-----------	---------------	----------------------	---------------

The Center of Molecular Immunology and its commercial branch CIMAB SA announced that both companies BIOCON India Ltd and CIMAB SA have finalized a joint venture agreement to establish a new Joint Venture company BIOCON Pharmaceuticals Ltd that will set up a new manufacturing facility to manufacture and market a select range of biotechnology products for human health care primarily in the Indian market.

In the JV agreement BIOCON India Ltd has tied-up with CIMAB SA in a 51:49 venture which also includes or will develop a monoclonal antibody for cancer treatment and other products from mammalian cell culture. ( MedTRACK Reference ID: prod\_84442003226)

2/26/2003	HER 1 cancer vaccine	Cimab S.A	Joint Venture	Cancer	not disclosed
-----------	----------------------	-----------	---------------	--------	---------------

The Center of Molecular Immunology and its commercial branch CIMAB SA announced that both companies BIOCON India Ltd and CIMAB SA have finalized a joint venture agreement to establish a new Joint Venture company BIOCON Pharmaceuticals Ltd that will set up a new manufacturing facility to manufacture and market a select range of biotechnology products for human health care primarily in the Indian market.

In the JV agreement BIOCON India Ltd has tied-up with CIMAB SA in a 51:49 venture which also includes or will develop a monoclonal antibody for cancer treatment and other products from mammalian cell culture. ( MedTRACK Reference ID: prod\_84442003226)

2/26/2003	q-T3 chimeric anti-CD3 Mab	Cimab S.A	Joint Venture	Transplantation	not disclosed
-----------	----------------------------	-----------	---------------	-----------------	---------------

The Center of Molecular Immunology and its commercial branch CIMAB SA announced that both companies BIOCON India Ltd and CIMAB SA have finalized a joint venture agreement to establish a new Joint Venture company BIOCON Pharmaceuticals Ltd that will set up a new manufacturing facility to manufacture and market a select range of biotechnology products for human health care primarily in the Indian market.

In the JV agreement BIOCON India Ltd has tied-up with CIMAB SA in a 51:49 venture which also includes or will develop a monoclonal antibody for cancer treatment and other products from mammalian cell culture. ( MedTRACK Reference ID: prod\_84442003226)

2/26/2003	TheraCIM (h-R3)	Cimab S.A	Joint Venture	Brain Tumor	not disclosed
-----------	-----------------	-----------	---------------	-------------	---------------

The Center of Molecular Immunology and its commercial branch CIMAB SA announced that both companies BIOCON India Ltd and CIMAB SA have finalized a joint venture agreement to establish a new Joint Venture company BIOCON Pharmaceuticals Ltd that will set up a new manufacturing facility to manufacture and market a select range of biotechnology products for human health care primarily in the Indian market.

In the JV agreement BIOCON India Ltd has tied-up with CIMAB SA in a 51:49 venture which also includes or will develop a monoclonal antibody for cancer treatment and other products from mammalian cell culture. ( MedTRACK Reference ID: prod\_84442003226)

2/26/2003	TheraCIM (h-R3) / h-R3 anti-EGFr Mab	Cimab S.A	Joint Venture	Head and Neck Cancer	not disclosed
-----------	--------------------------------------	-----------	---------------	----------------------	---------------

The Center of Molecular Immunology and its commercial branch CIMAB SA announced that both companies BIOCON India Ltd and CIMAB SA have finalized a joint venture agreement to establish a new Joint Venture company BIOCON Pharmaceuticals Ltd that will set up a new manufacturing facility to manufacture and market a select range of biotechnology products for human health care primarily in the Indian market.

In the JV agreement BIOCON India Ltd has tied-up with CIMAB SA in a 51:49 venture which also includes or will develop a monoclonal antibody for cancer treatment and other products from mammalian cell culture. ( MedTRACK Reference ID: prod\_84442003226)

2/26/2003	TheraCIM (h-R3) / h-R3 anti-EGFr Mab	Cimab S.A	Joint Venture	Non-Small-Cell Lung Cancer	not disclosed
-----------	--------------------------------------	-----------	---------------	----------------------------	---------------

The Center of Molecular Immunology and its commercial branch CIMAB SA announced that both companies BIOCON India Ltd and CIMAB SA have finalized a joint venture agreement to establish a new Joint Venture company BIOCON Pharmaceuticals Ltd that will set up a new manufacturing facility to manufacture and market a select range of biotechnology products for human health care primarily in the Indian market.

In the JV agreement BIOCON India Ltd has tied-up with CIMAB SA in a 51:49 venture which also includes or will develop a monoclonal antibody for cancer treatment and other products from mammalian cell culture. ( MedTRACK Reference ID: prod\_84442003226)

5/22/2002	Oral Insulin	Nobex Corporation GlaxoSmithKline plc	Commercialization, Development, License, Termination	Diabetes	283.0
-----------	--------------	--	--	----------	-------

GlaxoSmithKline and Nobex Corporation announced a strategic alliance for the development and commercialisation of orally administered insulin products for the treatment of diabetes. The first product to be developed in the collaboration is a novel modified oral insulin for controlling post-meal blood glucose. Nobex has already advanced this novel insulin into Phase I/II clinical trials.

GSK and Nobex will work collaboratively on product development and will continue to identify additional insulin molecules, modified with Nobex's proprietary technology, for development in the collaboration. Research for the identification of new insulin molecules for oral delivery will be funded by GSK, and Nobex may receive additional milestone payments and royalties if these efforts are successful. ( MedTRACK Reference ID: prod\_12612002522)

4/9/2002	Oratonin (NCT-025)	Nobex Corporation Elan Corp Plc	Collaboration, Development	Osteoporosis	not disclosed
----------	--------------------	------------------------------------	-------------------------------	--------------	---------------

NOBEX Corporation and Elan Corporation announced that their joint venture, Synerobex, has initiated dosing in a Phase I clinical trial in the development and commercialization of Oratonin, oral calcitonin, for the treatment of osteoporosis. The trial will explore the tolerance, safety and absorption of Oratonin. The Phase I study is the first exposure of NOBEX modified oral calcitonin in human subjects. This is a randomized, single-blind, placebo-controlled dose escalation study that will determine the safety, tolerability and pharmacokinetic profile of Oratonin in healthy volunteers. Responses to relevant pharmacodynamic parameters, such as blood calcium levels, will also be measured. ( MedTRACK Reference ID: prod\_5041200249)

#### Miscellaneous Deals

Date	Source/Partner	Deal Type(s)	Area of Interest	Deal Value (in \$mm)
1/5/2007	Neopharma	Joint Venture, Manufacturing, Marketing	Bio-pharmaceuticals	not disclosed



Biocon and Neopharma have signed an MOU to establish a JV to manufacture and market a range of Biopharmaceuticals for the GCC countries (Gulf Cooperation Council). This landmark agreement between the two companies heralds the region's first foray to develop and market life saving biopharmaceutical products.( MedTRACK Reference ID: comp\_27933200715)

9/4/2006	Innate Pharmaceuticals AB	Co-development, Collaboration, Manufacturing, Marketing	Bacterial Diarrhoeal Disease	not disclosed
----------	---------------------------	---	------------------------------	---------------

Syngene International a wholly owned subsidiary of Biocon and Innate Pharmaceuticals have concluded a cooperation agreement to jointly develop, manufacture and market virulence blockers to counteract bacterial diarrhoeal disease. Virulence blockers are a new class of drugs that could become an alternative to antibiotics.( MedTRACK Reference ID: comp\_26223200694)

6/27/2005	OmniComm Systems, Inc.	Collaboration, Letter of Intent	Global Clinical Trials	not disclosed
-----------	------------------------	---------------------------------	------------------------	---------------

Clinigene International, a wholly owned subsidiary of India's premier Biotech enterprise, Biocon limited and SCIREX Corporation, a wholly owned subsidiary of the Omnicom Group have announced that they have signed a Letter of Intent (LOI) to collaborate on global clinical trials.

With India rapidly emerging as a key locale for clinical research, the new relationship provides SCIREX clients immediate access to well developed expertise in clinical investigation in India and provides Clinigene the opportunity to expand its markets and partake in global clinical trial programs.( MedTRACK Reference ID: comp\_155402005627)

9/1/2004	Novartis AG	Research	Research	not disclosed
----------	-------------	----------	----------	---------------

Biocon's subsidiary Syngene International has entered into a contract research agreement with the Novartis Institutes for Biomedical Research to carry out research projects to support new drug discovery and development.( MedTRACK Reference ID: comp\_8236200491)

7/3/2002	Strand Life Sciences	Collaboration	Clinical Data Analysis	not disclosed
----------	----------------------	---------------	------------------------	---------------

Strand Genomics (Strand), a Bangalore-based bioinformatics company and Clinigene International Pvt Ltd, a subsidiary of Biocon India Ltd today announced that they have entered into a strategic partnership. Strand will analyze the clinical data generated by Clinigene in various Registries to discover patterns that can give insights into diseases. The goal of the partnership is to discover new biological wisdom from the clinical data, which would lead to novel diagnostics and therapies.

( MedTRACK Reference ID: comp\_7019200273)

3/4/2002	Nobex Corporation Albany Molecular Research Inc	Collaboration, Research	Polymer	not disclosed
----------	---	-------------------------	---------	---------------

NOBEX Corporation and Albany Molecular Research, Inc. entered into a collaborative research program to develop a comprehensive library of NOBEX proprietary polymers for use in pharmaceuticals as well as in additional applications in the life sciences, cosmetic, food and industrial sectors. The library will immediately enable NOBEX scientists to accelerate new drug development by readily accessing multiple, pre-synthesized polymers to attach to drugs and assess new drug delivery benefits. Under the terms of the agreement, Albany Molecular will provide NOBEX with a library of more than 500 unique combinations of small, water and fat-soluble polymers that can provide key delivery advantages to pharmaceutical products, such as compatibility with a variety of water soluble and/or fatty materials.( MedTRACK Reference ID: comp\_5034200234)

10/19/2000	National Institutes of Health (NIH) The U.S. Department of Health and Human Services Nobex Corporation	Development	Obesity, Pain	0.2
------------	--	-------------	---------------	-----

Nobex Corporation, formerly Protein Delivery, announced that the Company has been awarded two Small Business Innovation Research (SBIR) grants of \$100,000 each from the National Institutes of Health (NIH).

The grants will accelerate the development of two different Nobex drug candidates, one for the alleviation of severe pain and the second for the treatment of obesity.( MedTRACK Reference ID: comp\_1058120001019)

### **M&A Stats**

<b>Date</b>	<b>Acquirer/Merger Partner</b>	<b>Target/Merger Partner</b>	<b>Reason</b>
3/29/2006	Biocon Ltd (BCLTF)	Nobex Corporation	Acquisition

Biocon has won the bid for acquiring all the assets of Nobex for \$5 million and certain back-end royalties. Nobex specialises in a proprietary drug delivery system to enable oral delivery of peptide drugs. The assets acquired by Biocon include IN-105, an oral insulin for type 2 diabetes, BN-054, an oral B-type natriuretic peptide for cardiovascular disease, Oratonin, an oral calcitonin in phase 1 trials for osteoporosis, Oral PTH (Para Thyroid Hormone) and APAZA, an oral small molecule drug in phase 1/2 trials for inflammatory bowel disease.

12/6/2005	Biocon Ltd (BCLTF)	Nobex Corporation	Acquisition Agreements
-----------	--------------------	-------------------	------------------------

Biocon, plans to acquire the intellectual property of its research collaborator Nobex, which has applied for cover under Chapter 11 of the U.S. bankruptcy laws, Biocon informed the Bombay Stock Exchange. Biocon and Nobex have been co-developing the revolutionary tablet-form oral insulin - IN105 - for both Type 1 and Type 2 diabetics. The company said it has invested \$5.8 million in Nobex - \$1 million as common stock and the rest in convertible loans.

### **Recent Partnering Updates**

1/19/2007 (Category: Deals & Alliances)	On January 19, 2007 Biocon announced that it has granted an exclusive license to Ferozsons Laboratories for marketing BIOMAb EGFR in Pakistan. The successful debut of the cancer drug in the Indian market in September 2006 has evinced strong licensing interest, according to Biocon. The company's decision to license the drug to Ferozsons is due to its rank as the No. 1 oncology firm in Pakistan. The Pakistan oncology market is valued at approximately USD70 million, according to Biocon.
1/5/2007 (Category: Deals & Alliances)	On January 05, 2007 Biocon Limited and Neopharma announced that they have signed an MOU to establish a JV to manufacture and market a range of Bio-pharmaceuticals for the GCC countries (Gulf Cooperation Council). This landmark agreement between the two companies heralds the region's first foray to develop and market life saving biopharmaceutical products.
9/4/2006 (Category: Deals & Alliances)	On September 4, 2006 Syngene International Private Limited, a wholly owned subsidiary of Biocon Limited and Innate Pharmaceuticals AB, Umea, Sweden have concluded a cooperation agreement to jointly develop, manufacture and market virulence blockers to counteract bacterial diarrhoeal disease. Virulence blockers are a new class of drugs that could become an alternative to antibiotics. Clinical studies of therapeutic effect will be conducted over the next three years and a candidate drug will be developed to the stage of a limited Phase II study in patients with diarrhoeal disease. Once therapeutic effect is demonstrated, Syngene will carry out further clinical studies enabling the virulence blocker to be registered as a drug for the treatment of bacterial diarrhoeal disease. Innate Pharmaceuticals will have European marketing rights, while Syngene will have rights to other parts of the world market. Each company will receive royalties on the sales conducted by the other.
7/19/2006 (Category: Deals & Alliances)	On July 19, 2006 Biocon Ltd announced a licensing agreement with multinational healthcare corporation Bayer HealthCare (BHC) for the exclusive marketing and trademark rights for Insugen for the Chinese market. It is envisaged that the collaboration will be expanded to other countries in Asia Pacific. After completion of necessary local registration trials, Insugen, a recombinant human insulin, is expected to be launched within the next two to three years in China.
3/28/2006 (Category: Mergers & Acquisitions)	On March 28, 2006 Biocon Limited announced that it had put up the winning bid for acquiring all the assets of Nobex Corporation, a drug development company specializing in a proprietary drug delivery system to enable oral delivery of peptide drugs. Biocon and Nobex had earlier entered into an alliance for the global co-development and commercialisation of oral insulin and oral B-type natriuretic peptide (BNP).
11/14/2005 (Category: Deals & Alliances)	On November 14, 2005 Bentley Pharmaceuticals, Inc. announced that it has signed a product licensing agreement with Biocon Limited for Bentley's intranasal spray formulation for administering insulin. The license agreement covers 85 countries granting Biocon exclusive as well as co-exclusive rights to develop and market Bentley's formulation throughout Asia, Africa, and the Middle East. Bentley also announced that it has entered into a long term supply agreement with Biocon, which will provide Bentley, and its licensees, with a competitive commercial supply of insulin for worldwide markets.

<p>8/23/2005 (Category: Deals &amp; Alliances) On August 23, 2005 Biocon Limited and North Carolina's Nobex Corporation have announced a global research collaboration to jointly develop an oral peptide product for the treatment of cardiovascular disease. The collaboration combines the proven peptide production capabilities of Biocon with the proprietary oral peptide-delivery technology of Nobex. Biocon and Nobex plan to advance the oral human brain-type natriuretic peptide (hBNP) program towards an IND (Investigational New Drug) filing with the FDA (US Food and Drug Administration) in 2007 and clinical trials beginning later that year.</p>
<p>8/23/2005 (Category: Deals &amp; Alliances) On August 23, 2005 Nobex Corporation and Biocon Limited announced that they have signed a new agreement for the global co-development of an oral brain-type natriuretic peptide (BNP) product for the treatment of cardiovascular disease. The financial terms of the agreement were not disclosed.</p>
<p>6/27/2005 (Category: Deals &amp; Alliances) On June 27, 2005 Clinigene International, Biocon limited and Scirex Corporation announced that they have signed a Letter of Intent to collaborate on global clinical trials.</p>
<p>6/1/2005 (Category: Deals &amp; Alliances) On June 1, 2005 Biocon Limited announced that the company has signed a Memorandum of Understanding with the Karolinska Institute in Sweden to collaborate in research and research education initiatives. The Memorandum of Understanding was signed between the two organizations on May 27, 2005 at the Karolinska Institute, Sweden.</p>
<p>11/18/2004 (Category: Deals &amp; Alliances) On November 18, 2004 Biocon Limited and Vaccinex, Inc. announced a broad strategic partnership to discover and co-develop at least four therapeutic antibody products. The collaboration combines Vaccinex's unique capabilities to discover fully human monoclonal antibodies using its proprietary antibody discovery technology, and Biocon's proven expertise in clinical research and biologics manufacturing. The parties will jointly work to identify promising antibody candidates and move them rapidly into clinical development. The parties plan to focus on antibody products directed to cancer, inflammation and autoimmune disease. As part of the collaboration, Biocon will also make an equity investment in Vaccinex.</p>
<p>10/20/2004 (Category: Deals &amp; Alliances) On October 20, 2004 Biocon announced that it has reached an agreement between a pioneering US Biotech firm, targets an exciting and commercially viable new delivery for Insulin. The collaboration combines the proven peptide production capabilities of Biocon, with the proprietary peptide oral-delivery technology of Nobex. The two companies will focus on the development of an oral insulin product that can be used to treat a diabetic population that is estimated to increase to more than 200 million worldwide by the year 2030.</p>
<p>10/20/2004 (Category: Deals &amp; Alliances) On October 20, 2004 Nobex Corporation and Biocon, Limited announced that they have entered into a joint development agreement for the global co-development of an oral insulin product for the treatment of diabetes. The collaboration combines the proprietary peptide oral-delivery and manufacturing technology of U.S.-based Nobex with the proven peptide production capabilities of Biocon, India's leading biotechnology company. The firms will focus on the development of an oral insulin product that can be used to treat a diabetic population that will increase to more than 200 million worldwide by the year 2030. Both companies indicated that the collaborative effort in developing the oral insulin product will require several years to reach the market but that they expect to have meaningful clinical data and progress toward manufacturing within two years. The financial terms of the agreement were not disclosed.</p>
<p>8/31/2004 (Category: Deals &amp; Alliances) On August 31, 2004 Biocon announced that Syngene International has announced that it has entered into a contract research agreement with the Novartis Institutes for Biomedical Research, Inc. to carry out research projects to support new drug discovery and development. The contract research agreement was signed recently after a senior contingent from Cambridge, MA, the global headquarters of the Novartis Institutes, visited Syngene in Bangalore last month. Novartis joins the ranks of leading multinational pharmaceutical companies that form part of Syngene's client portfolio in this area. "We are delighted and proud to work with Novartis. This alliance is yet another step in our evolution as a valuable partner to the global pharmaceutical industry and will further enhance Syngene's ability to conduct world-class research," said Kiran Mazumdar-Shaw, CMD of Biocon Ltd.</p>
<p>7/25/2004 (Category: Deals &amp; Alliances) On July 25, 2004 Biocon Limited announced that in an unusual commercial transaction between Cuba and USA, CancerVax Corporation received a rare U.S. Government Approval to license three experimental cancer drugs from a leading Cuban Institute, CIMAB (Centre for Molecular Immunology) - a deal believed to be a first for a U.S. biotech company and Cuba.</p>
<p>6/21/2004 (Category: Deals &amp; Alliances) On June 21, 2004 Biocon Biopharmaceuticals, the Joint Venture with CIMAB, announced that it has extended its product portfolio to include 2 additional monoclonal antibodies and 3 Cancer Vaccines. An agreement was signed between the two partners, Kiran Mazumdar-Shaw representing Biocon and Patricia Sierra representing CIMAB in a formal ceremony in Havana on 2nd June 2004 in the presence of The Indian Ambassdor, Mr. Balakrishnan and the Secretary of the Council of the State of Cuba, Dr. Jose M. Miyar. Representatives of both countries praised the importance of this partnership as an outstanding example of South-South co-operation in the field of Biotechnology.</p>
<p>2/17/2004 (Category: Deals &amp; Alliances) On February 17, 2004 The Dow Chemical Company and Nobex Corporation announced that they will collaborate on plant-based production of NLC-001, a proprietary peptide currently in preclinical development by Nobex as a potential appetite suppressant to treat obesity. This project</p>

broadens the scope of Dow Plant Biopharmaceuticals beyond their current work in plant-based pharmaceutical production, which has focused primarily on antibodies. Nobex will provide a proprietary gene sequence that will be used in combination with Dow Plant Biopharmaceuticals' proprietary expression technology. Financial terms are not being disclosed. Under the agreement, the initial expression of the peptide will take place in plant cell suspension to allow for fast evaluation of the ability of plant tissues to secrete the peptide. If successful, production may be moved to whole plants for rapid scale-up.

11/14/2003 (Category: Deals & Alliances) On November 14, 2003 Nobex announced that it will reacquire all rights, intellectual property, data, and all other assets related to its modified insulin molecules for all routes of delivery that had been licensed to GSK or produced by GSK during the parties' 17-month alliance. This transaction followed a decision by GSK to end the alliance based on internal business reasons.

5/22/2002 (Category: Deals & Alliances) On May 22, 2002 GlaxoSmithKline and Nobex Corporation announced a strategic alliance for the development and commercialisation of orally administered insulin products for the treatment of diabetes.

3/25/2002 (Category: Deals & Alliances) On March 25, 2002 Nobex Corporation announced the formation of a collaboration with Pharmacia Corporation. Proprietary medicinal chemistry developed by Nobex will be used to modify an undisclosed Pharmacia protein to improve its oral delivery in pill or liquid form. Under the terms of the agreement, Pharmacia will fund research at Nobex and has an option to license the Nobex- modified drug at the completion of the study. Financial terms of the deal were not disclosed.